Dr. Fariba Ghodsian is the Chief Investment Officer and a Managing Member of DAFNA Capital Management.
Dr. Ghodsian received her M.B.A. from the University of California at Los Angeles in 1991, and completed her postdoctoral fellowship in protein modeling at Harvard Medical School in 1988. She received her Ph.D. in Biomedical Engineering from Oxford University in England in 1987, her M.S. in Chemical Engineering from Massachusetts Institute of Technology in 1985, and her B.S. in Chemical Engineering from Technion, Israel Institute of Technology in 1983.
Prior to joining the firm in 2002, Dr. Ghodsian was Managing Director of Healthcare Research at Roth Capital Partners in Los Angeles. Before this, she was a senior biotechnology analyst at Lehman Brothers, Hancock Institutional, and Wedbush Morgan Securities, as well as Director of Business Development at Medclone and a research scientist at Allergan Pharmaceuticals.
In 2002, Dr. Ghodsian received the Wall Street Journal’s “Best on the Street” award, as one of the top five biotechnology analysts. She has been a frequent guest speaker at conferences, has authored multiple scientific publications, and holds several patents. She currently serves on the board of two educational non-profit organizations and has served on the NIH’s Scientific Grant Review Board.